Display options
Cite
Wang J, Li YC, Deng M, et al. Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8(46):81098-81108doi: 10.18632/oncotarget.19186.
Wang, J., Li, Y. C., Deng, M., Jiang, H. Y., Guo, L. H., Zhou, W. J., & Ruan, B. (2017). Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget, 8(46), 81098-81108. https://doi.org/10.18632/oncotarget.19186
Wang, Jing, et al. "Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis." Oncotarget vol. 8,46 (2017): 81098-81108. doi: https://doi.org/10.18632/oncotarget.19186
Wang J, Li YC, Deng M, Jiang HY, Guo LH, Zhou WJ, Ruan B. Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2017 Jul 12;8(46):81098-81108. doi: 10.18632/oncotarget.19186. eCollection 2017 Oct 06. PMID: 29113370; PMCID: PMC5655265.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 12;8(46):81098-81108. doi: 10.18632/oncotarget.19186. eCollection 2017 Oct 06.

Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis.

Oncotarget

Jing Wang, Yu-Chuan Li, Min Deng, Hai-Yin Jiang, Li-Hua Guo, Wen-Juan Zhou, Bing Ruan

Affiliations

  1. Department of Cardiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  2. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  3. Department of Health Management Center, Wuxi Third People's Hospital, Wuxi, Jiangsu, China.

PMID: 29113370 PMCID: PMC5655265 DOI: 10.18632/oncotarget.19186

Abstract

PURPOSE: Previous studies have supported an association between serum insulin-like growth factor-1 (IGF1) and IGF-binding protein 3 (IGFBP3) levels and hepatocellular carcinoma (HCC), but the results were inaccurate. It has recently been proposed that IGF1 and IGFBP3 play roles in the time-to-progression (TTP) and overall survival (OS) of HCC patients. Our results revealed that serum IGF1 level is predictive of the progression and survival of HCC patients.

RESULTS: HCC was associated with a significant reduction in serum IGF-1 and IGFBP-3 levels compared to cirrhosis (

MATERIALS AND METHODS: We conducted a comprehensive literature search in PubMed, EMBASE, and the Cochrane Library. Twenty studies met the inclusion criteria and were subjected to statistical analysis. The geometric mean and standard deviation (SD) of serum IGF1 and IGFBP3 levels in the healthy, cirrhosis, and HCC groups were calculated. Pooled odds ratios (ORs) were calculated using a fixed-effects model to analyse the association of serum IGF1 level with the progression and survival of HCC patients.

CONCLUSIONS: Serum IGF1 and IGFBP3 levels were positively associated with the incidence of HCC. Serum IGF1 level is an independent prognostic factor for the progression and survival of HCC patients.

Keywords: IGF-binding protein-3; hepatocellular carcinomas; insulin-like growth factor-1; overall survival; time-to-progression

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

References

  1. PLoS One. 2014 Mar 04;9(3):e90862 - PubMed
  2. J Natl Cancer Inst. 2014 May 09;106(5):null - PubMed
  3. J Clin Oncol. 2011 Oct 10;29(29):3892-9 - PubMed
  4. Cancer Sci. 2006 Nov;97(11):1182-90 - PubMed
  5. Br J Cancer. 2010 Sep 28;103(7):1089-92 - PubMed
  6. J Natl Cancer Inst. 2000 Sep 20;92 (18):1472-89 - PubMed
  7. Int J Cancer. 2014 Jan 1;134(1):164-73 - PubMed
  8. Lancet Oncol. 2010 Jun;11(6):530-42 - PubMed
  9. Exp Ther Med. 2016 Feb;11(2):607-612 - PubMed
  10. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  11. J Cancer Res Clin Oncol. 2006 Nov;132(11):699-708 - PubMed
  12. Eur J Clin Nutr. 2007 Jan;61(1):91-8 - PubMed
  13. Tumour Biol. 2016 Nov;37(11):15125-15132 - PubMed
  14. J Clin Oncol. 2010 Nov 20;28(33):4985-95 - PubMed
  15. Cancer. 2002 Dec 15;95(12):2539-45 - PubMed
  16. J Natl Cancer Inst. 1999 Apr 7;91(7):620-5 - PubMed
  17. Oncotarget. 2015 Aug 28;6(25):21193-207 - PubMed
  18. Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):639-57 - PubMed
  19. Endocr Rev. 2007 Feb;28(1):20-47 - PubMed
  20. Oncol Rep. 2013 Sep;30(3):1337-45 - PubMed
  21. Oncology. 2011;80(5-6):373-81 - PubMed
  22. Eur J Hum Genet. 2009 Dec;17(12):1668-75 - PubMed
  23. J Clin Lab Anal. 2010;24(3):195-200 - PubMed
  24. Int J Cancer. 2000 Jul 1;87(1):118-21 - PubMed
  25. Eur J Endocrinol. 2009 Nov;161(5):705-13 - PubMed
  26. Asian Pac J Cancer Prev. 2015;16(2):613-9 - PubMed
  27. J Hepatocell Carcinoma. 2015 Sep 18;2:131-42 - PubMed
  28. Clin Cancer Res. 2012 Jul 15;18(14):3992-7 - PubMed
  29. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2877-87 - PubMed
  30. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1333-40 - PubMed
  31. J BUON. 2010 Jan-Mar;15(1):141-6 - PubMed
  32. Hepatogastroenterology. 2011 May-Jun;58(107-108):949-54 - PubMed
  33. Clin Endocrinol (Oxf). 2003 Dec;59(6):699-706 - PubMed
  34. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  35. Clin Cancer Res. 2013 Aug 1;19(15):4218-27 - PubMed
  36. Dig Dis Sci. 2001 Jun;46(6):1313-20 - PubMed
  37. Stat Med. 1987 Apr-May;6(3):341-50 - PubMed
  38. Nat Rev Cancer. 2004 Jul;4(7):505-18 - PubMed
  39. Oncol Lett. 2012 Mar;3(3):704-712 - PubMed
  40. Hepatology. 2005 Nov;42(5):1208-36 - PubMed
  41. Biometrics. 2000 Jun;56(2):337-44 - PubMed

Publication Types